The U.S. brand name for this drug is Eylea, and it is administered by injection into the treatment area. This medicine is a VEGF inhibitor that controls blood flow to the retina by preventing the development of new blood vessels. When these blood vessels are prevented from forming under the retina, blood flow is restricted to these parts. This prevents the leakage of blood and fluids from the retina.
It is a prescription-only medication that is administered by a healthcare professional and belongs to the drug class anti-angiogenic ophthalmic agents. It is available as generic drugs with aflibercept as the active ingredient. It is currently presented in solution form in glass vials.
This drug is FDA approved and got its first approval on November 18th, 2011. The drug is contraindicated for people with swellings in their eyes, bacterial, viral or fungal infections and those allergic to the medication.
Some side effects do not constitute a medical emergency. They go away in time as the body gets used to the medication. If these minor side effects do become bothersome, the advice of a healthcare professional should be sought on steps to take to prevent their occurrence or reduce their impact. These are the following:
Other side effects not listed here may occur, and the healthcare professional treating the patient should be notified.
Dosage considered here is 40mg/mL.
The dosage form is an intravitreal injectable solution.
Safety and efficacy for use in children and persons less than 18 years of age have not been established. The drug is not recommended for use for such.
2mg (0.5 mL) given by intravitreal injection after every four weeks (monthly) for the first three months (twelve weeks) of treatment. This should be followed by the same dosage, 2mg (0.5mL) every two months (8 weeks).
2mg (0.5mL) given monthly (every four weeks) by intravitreal injection
2mg (0.5mL) given by intravitreal injection every month (4 weeks) for the first five months. This should be followed by 2mg (0.5mL) given by intravitreal injection every two months (8 weeks).
Additional comment: There was no additional efficacy when dosing was done every four weeks as compared to eight weeks.
There are no recommendations for this.
No recommendations are available.
There are no known Eylea drug interactions. However, this should not imply that a medical practitioner should not be informed of what a patient is taking while on treatment. The medical practitioner must be notified of all other drugs, vitamins, minerals and other natural products that a patient is taking before and while they receive treatment with Eylea (aflibercept ophthalmic).
Natural and organic products should not be considered safe and must be listed for a medical practitioner to determine safety.
Eylea has one known disease interaction. It interacts with ocular infections.
Animal studies done showed evidence of embryofetal toxicity when aflibercept is administered during gestation. There are no controlled studies done for pregnant women. It is an AU TGA pregnancy category D drug. These are drugs that are very likely to be unsafe in pregnancy and may increase the incidence of irreversible damage or fetal malformations in humans. The pharmacological effects of these drugs are also adverse.
It is a U.S. FDA category C drug. Animal studies show this drug harms the fetus when administered during gestation. There are no well-controlled, adequate studies done on humans to determine the safety of aflibercept during pregnancy conclusively. Pregnant women may receive this drug, however, if the benefits of using it outweigh the risks. For the most part, however, it is to be avoided during pregnancy.
Women of childbearing age should use an effective contraceptive if they are to receive aflibercept treatment. They should continue taking the contraceptives three months after the last injection to ensure they do not conceive at this time.
This drug should not be used by a mother who has a breastfeeding child as there are no studies to determine if it passes into breast milk, and what effect it would have on the child if it does. If a mother must use this drug, it is recommended that she discontinue breastfeeding.
Aflibercept should be refrigerated at 2 to 8 degrees centigrade, but not frozen. Additionally, it should be well protected from light and stored in its original carton until the day of use. It should not be used after the use by date which is usually stamped on the container.
Eylea (Aflibercept ophthalmic) is a safe intervention for the medical conditions it is meant to treat. However, this does not imply that a patient can start or stop this medication anytime, or mix it with any other without proper consultation with a healthcare provider. No medicine is too safe that the advice of a trained professional is not required.
A patient receiving aflibercept should also not try to add other medications to their eyes without consulting a medical practitioner. Even though aflibercept has no known interactions, it would still be unsafe for a patient to prescribe themselves some medication. It is particularly dangerous to use someone else's medicine. Patients receiving this drug are not advised to medicate on their own even when faced with the not so serious side effects. Only a doctor should offer solutions in response to any side effects.
A drug only works well if it is used correctly and at the right dosages, which should just be prescribed by a medical practitioner. The information contained herein on aflibercept is in no way conclusive. It is not meant to endorse aflibercept for treatment of any disease or medical condition. Only a doctor can determine what is best in a given situation.
The information should be used as a general guide but should never replace getting the advice of a healthcare professional.